GaÃ«tan Marie MacGrogan

List of Publications by Year
in descending order

19 papers	**1,949** citations	687363 **13** h-index	713466 **21** g-index
23 all docs	**23** docs citations	**23** times ranked	**3223** citing authors

#	ARTICLE	IF	CITATIONS
1	Identification of molecular apocrine breast tumours by microarray analysis. Oncogene, 2005, 24, 4660-4671.	5.9	694
2	A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nature Medicine, 2009, 15, 68-74.	30.7	566
3	Prognostic and Predictive Value of Centrally Reviewed Ki-67 Labeling Index in Postmenopausal Women With Endocrine-Responsive Breast Cancer: Results From Breast International Group Trial 1-98 Comparing Adjuvant Tamoxifen With Letrozole. Journal of Clinical Oncology, 2008, 26, 5569-5575.	1.6	299
4	Solid papillary carcinoma with reverse polarity of the breast harbors specific morphologic, immunohistochemical and molecular profile in comparison with other benign or malignant papillary lesions of the breast: a comparative study of 9 additional cases. Modern Pathology, 2018, 31, 1367-1380.	5.5	42
5	SOX10, GATA3, GCDFP15, Androgen Receptor, and Mammaglobin for the Differential Diagnosis Between Triple-negative Breast Cancer and TTF1-negative Lung Adenocarcinoma. American Journal of Surgical Pathology, 2019, 43, 293-302.	3.7	41
6	Solid-type adenoid cystic carcinoma of the breast, a distinct molecular entity enriched in NOTCH and CREBBP mutations. Modern Pathology, 2020, 33, 1041-1055.	5.5	39
7	Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials. Breast Cancer Research and Treatment, 2015, 154, 275-286.	2.5	37
8	The mammary ducts create a favourable microenvironment for xenografting of luminal and molecular apocrine breast tumours. Journal of Pathology, 2016, 240, 256-261.	4.5	31
9	Residual cancer burden index and tumor-infiltrating lymphocyte subtypes in triple-negative breast cancer after neoadjuvant chemotherapy. Breast Cancer Research and Treatment, 2020, 179, 11-23.	2.5	28
10	Interobserver variability in upfront dichotomous histopathological assessment of ductal carcinoma in situ of the breast: the DCISion study. Modern Pathology, 2020, 33, 354-366.	5.5	25
11	Triple-negative breast lobular carcinoma: a luminal androgen receptor carcinoma with specific ESRRA mutations. Modern Pathology, 2021, 34, 1282-1296.	5.5	22
12	Neurotensin Receptor-1 Expression in Human Prostate Cancer: A Pilot Study on Primary Tumors and Lymph Node Metastases. International Journal of Molecular Sciences, 2019, 20, 1721.	4.1	14
13	Interobserver variability in the assessment of stromal tumor-infiltrating lymphocytes (sTILs) in triple-negative invasive breast carcinoma influences the association with pathological complete response: the IVITA study. Modern Pathology, 2021, 34, 2130-2140.	5.5	14
14	Humanization of the mouse mammary gland by replacement of the luminal layer with genetically-engineered preneoplastic human cells. Breast Cancer Research, 2014, 16, 504.	5.0	13
15	LIN7A is a major determinant of cell-polarity defects in breast carcinomas. Breast Cancer Research, 2016, 18, 23.	5.0	13
16	Molecular apocrine tumours in EORTC 10994/BIG 1-00 phase III study: pathological response after neoadjuvant chemotherapy and clinical outcomes. British Journal of Cancer, 2019, 120, 913-921.	6.4	11
17	Breast hamartoma: reassessment of an under‐recognised breast lesion. Histopathology, 2021, , .	2.9	4
18	Expression of neurotensin receptor-1 (NTS1) in primary breast tumors, cellular distribution, and association with clinical and biological factors. Breast Cancer Research and Treatment, 2021, 190, 403-413.	2.5	2

#	Article	IF	Citations
19	Neoadjuvant chemotherapy and radiotherapy for locally advanced breast cancer: Safety and efficacy of reverse sequence compared to standard technique?. European Journal of Surgical Oncology, 2022, , .	1.0	1